Publications
Detailed Information
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Y. | - |
dc.contributor.author | Kim, T. M. | - |
dc.contributor.author | Jeon, Y. K. | - |
dc.contributor.author | Kwon, T. -K. | - |
dc.contributor.author | Hah, J. H. | - |
dc.contributor.author | Lee, S. -H. | - |
dc.contributor.author | Kim, D. -W. | - |
dc.contributor.author | Wu, H. -G. | - |
dc.contributor.author | Rhee, C. -S. | - |
dc.contributor.author | Sung, M. -W. | - |
dc.contributor.author | Kim, C. W. | - |
dc.contributor.author | Kim, K. H. | - |
dc.contributor.author | Heo, D. S. | - |
dc.date.accessioned | 2020-04-27T11:40:27Z | - |
dc.date.available | 2020-04-27T11:40:27Z | - |
dc.date.created | 2020-02-19 | - |
dc.date.issued | 2009-08 | - |
dc.identifier.citation | Annals of Oncology, Vol.20 No.8, pp.1414-1419 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | 91882 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165552 | - |
dc.description.abstract | Materials and methods: Retrospective review of medical records at Seoul National University Hospital between 1998 and 2007 was carried out. Immunohistochemical stain of TUBB3, p53, and ERCC1 was done in paraffin-embedded tumor tissue. We assessed response to treatment, progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS). Results: Eighty-five patients with oropharyngeal, hypopharyngeal, and laryngeal cancers received induction chemotherapy with 5-fluorouracil (5-FU) and cisplatin (n = 55), or 5-FU, cisplatin, and docetaxel (Taxotere) (n = 30). Eighty-three received definitive treatment after induction chemotherapy, where 62 received radiotherapy and 21 received surgery. TUBB3-positive patients showed lower response rate than TUBB3-negative patients (69% versus 88%, P = 0.039). Shorter median PFS was observed in TUBB3-positive group (12 versus 47 months, P = 0.001). Shorter median OS was observed in TUBB-positive group not reaching statistical significance (30 versus 59 months, P = 0.072). TUBB3 status significantly influenced CSS (35 months versus not reached, P = 0.017). Positive p53 status was related to poorer OS and CSS. ERCC1 showed no influence on chemotherapy response, PFS, OS, and CSS. Conclusion: TUBB3 is a predictive and prognostic marker along with well-known p53 in HNSCC patients receiving cisplatin-based induction chemotherapy. Clinical impact of ERCC1 is not evident in this setting. | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 우홍균 | - |
dc.contributor.AlternativeAuthor | 이재서 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 김철우 | - |
dc.contributor.AlternativeAuthor | 성명훈 | - |
dc.contributor.AlternativeAuthor | 김광현 | - |
dc.contributor.AlternativeAuthor | 전윤경 | - |
dc.contributor.AlternativeAuthor | 권택균 | - |
dc.contributor.AlternativeAuthor | 하정훈 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.identifier.doi | 10.1093/annonc/mdp002 | - |
dc.citation.journaltitle | Annals of Oncology | - |
dc.identifier.wosid | 000268806700017 | - |
dc.identifier.scopusid | 2-s2.0-69449099543 | - |
dc.citation.endpage | 1419 | - |
dc.citation.number | 8 | - |
dc.citation.startpage | 1414 | - |
dc.citation.volume | 20 | - |
dc.identifier.sci | 000268806700017 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Jeon, Y. K. | - |
dc.contributor.affiliatedAuthor | Kwon, T. -K. | - |
dc.contributor.affiliatedAuthor | Hah, J. H. | - |
dc.contributor.affiliatedAuthor | Kim, D. -W. | - |
dc.contributor.affiliatedAuthor | Wu, H. -G. | - |
dc.contributor.affiliatedAuthor | Rhee, C. -S. | - |
dc.contributor.affiliatedAuthor | Sung, M. -W. | - |
dc.contributor.affiliatedAuthor | Kim, C. W. | - |
dc.contributor.affiliatedAuthor | Kim, K. H. | - |
dc.contributor.affiliatedAuthor | Heo, D. S. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | HUMAN-PAPILLOMAVIRUS INFECTION | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | INDUCTION CHEMOTHERAPY | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | P53 GENE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordAuthor | beta-Tubulin | - |
dc.subject.keywordAuthor | ERCC1 | - |
dc.subject.keywordAuthor | head and neck cancer | - |
dc.subject.keywordAuthor | locally advanced | - |
dc.subject.keywordAuthor | prognosis | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.